Study #2022-1075
A multicenter, randomized, double-blinded, propofol-controlled, phase 3 clinical study to evaluate the efficacy and safety of HSK3486 injectable emulsion for induction of general anesthesia in adults undergoing elective surgery
MD Anderson Study Status
Not Accepting
Treatment Agent
HSK3486, Propofol
Description
To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
General Anesthesia
Study phase:
Phase III
Physician name:
Juan Cata
Department:
Anesthesiology & PeriOper Med
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.